Emerging within the UK, retatrutide, a novel compound , is sparking considerable interest within the healthcare community regarding its potential for physique control . This dual GIP and GLP-1 agent agonist appears to offer a considerable advantage over existing therapies, showing positive results in preliminary clinical assessments. Researchers be